세계의 면역치료제 시장 : 시장 규모, 쉐어, 동향 분석(약제유형별, 적응증별, 지역별), 부문별 예측(2025-2030년)

Immunotherapy Drugs Market Size, Share & Trends Analysis Report By Drug Type (Monoclonal Antibodies, Immunomodulators), By Indication (Infectious Diseases, Cancer), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,302,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,698,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,488,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

면역치료제 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계 면역치료제 시장 규모는 2030년까지 5,772억 달러에 이르며, 2025년부터 2030년까지 CAGR은 13.6%로 확대될 것으로 추정됩니다.

이 업계의 유리한 성장에 기여하는 주요 요인으로는 암, 자가면역질환, 염증성질환, 감염증 등의 만성질환에 대한 의식이 높아지고, 의약품 승인에 대한 정부의 지원 정책 등이 있습니다. 만성 질환 치료에 대한 표적 치료의 채용이 증가함에 따라 면역치료제에 대한 관심이 높아지고 예측 기간 동안 업계를 견인할 것으로 기대됩니다.

예를 들어, 2022년 5월, AstraZeneca Daiichi Sankyo의 Enhertu(트라스투주맙)는 HER2 양성 유방암 치료제로 미국에서 승인을 받았습니다. 다른 표적 면역요법 약물로는 Kadcyla(트라스투주맙 엠탄신), Tecentriq(아테졸리주맙) 등이 있습니다. 2022년 6월 F. Hofman La Roche는 NSCLC의 수술 후 보조 치료제로 Tecentriq의 EU 승인을 받았습니다. 게다가 중저소득국의 헬스케어 인프라가 발전하고 있으며 주요 기업에 의한 연구개발이 활발해지고 있는 것이 업계의 성장에 기여할 것으로 예상됩니다. 예를 들어, 2021년 12월 Novartis AG는 오시펠리맙(BGB-A1217)에 대해 BeiGene, Ltd.와 제휴하여 면역종양학의 연구개발 활동을 확대했습니다.

2021년 8월, Pfizer, Inc.는 원형 탈모증 치료제 리트레시티닙의 2b/3상 임상시험의 좋은 결과를 발표했습니다. 게다가 세계의 암 이환율 증가가 면역치료제 수요를 견인할 것으로 예상되고 있습니다. Globocan의 보고에 의하면, 2020년에는 새롭게 1,930만명의 암 환자가 진단될 것으로 추정되고 있습니다. 게다가 European Society of Medical Oncology에 따르면, 유럽에서의 암 이환율은 2020년부터 2040년 사이에 21% 상승할 것으로 예측되고 있습니다. 이와 같이 암 치료를 위한 다양한 면역치료제의 승인은 업계의 성장을 증가시킬 것으로 예측되고 있습니다.

면역요법 약물 시장 : 분석 개요

• 단클론항체 부문은 2024년에 76.2%의 최대 점유율을 차지했습니다. 이 성장은 치료용 단클론항체의 연구개발 증가와 정부의 지원책 때문입니다.
• 이러한 성장은 심혈관 질환, 호흡기 질환, 자가면역 질환과 같은 다양한 만성 질환에 대한 생물학적 제제 치료에 대한 수요가 높기 때문입니다.
• 암 분야는 세계의 암 이환율 증가와 중저소득국가의 헬스케어 인프라 개선으로 2024년 매출의 91.4%를 차지하고 시장을 독점하고 있습니다.
• 북미의 면역요법 시장은 2024년 매출 점유율 49.9%로 세계 시장을 독점했습니다.
• 이는 이 지역에서의 면역요법의 채용 증가, 지원적인 상환 정책, 헬스케어 지출 증가에 의한 것입니다.

목차

제1장 분석 방법·범위

제2장 주요 요약

제3장 면역치료제 시장 : 변동 요인?경향?범위

• 시장 개요/연관 전망
• 시장 규모와 성장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 면역치료제 시장 : 분석 도구
  • Porter's Five Forces 분석
  • PESTEL 분석

제4장 면역치료제 시장 : 약제유형별 추정·동향 분석

• 시장 점유율 : 약제유형별(2024년·2030년)
• 약제유형별 대시보드
• 시장 규모 예측과 동향 분석 : 약제 유형별(2018-2030년)
• 단클론항체
• 면역조절제
• 백신

제5장 면역치료제 시장 :적응증별 추정·동향 분석

• 시장 점유율 : 적응증별(2024년·2030년)
• 적응증별 대시보드
• 시장 규모 예측과 동향 분석 : 적응증별(2018-2030년)
• 암
• 자가면역질환
• 감염증
• 기타

제6장 면역치료제 시장 :지역별 추정·동향 분석

• 시장 점유율 : 지역별(2024년·2030년)
• 시장 대시보드:지역별
• 시장 규모 예측과 동향 분석(2018-2030년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 태국
  • 한국
  • 호주
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제7장 경쟁 구도

• 참가 기업 개요
• 기업 시장 포지션 분석
• 기업 분류
• 전략 매핑
• 기업 프로파일/상장 기업
  • Amgen Inc.
  • Novartis AG
  • AbbVie Inc.
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson Services, Inc.
  • AstraZeneca
  • GSK plc.
  • Sanofi
  • Bayer AG

JHS

영문 목차

영문목차

Immunotherapy Drugs Market Growth & Trends:

The global immunotherapy drugs market size is estimated to reach USD 577.2 billion by 2030, expanding at a CAGR of 13.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. The key factors contributing to the lucrative growth of the industry include increased awareness about chronic diseases including cancer, autoimmune diseases, inflammatory diseases, and infectious diseases, coupled with supportive government policies for drug approval. The rising adoption of targeted therapies for chronic disease treatment is expected to increase inclination toward immunotherapy drugs, thereby driving the industry during the forecast period.

For instance, in May 2022, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab) received U.S. approval for treating HER2-positive breast cancer. Other targeted immunotherapy drugs include Kadcyla (trastuzumab emtansine) and Tecentriq (atezolizumab). In June 2022, F. Hoffmann-La Roche Ltd. received EU approval for Tecentriq as an adjuvant treatment for NSCLC. In addition, developing healthcare infrastructure in low- and middle-income countries coupled with increased research & development by key players is anticipated to contribute to the industry growth. For instance, in December 2021, Novartis AG collaborated with BeiGene, Ltd. for ociperlimab (BGB-A1217), therefore expanding its R&D activities in immune-oncology.

In August 2021, Pfizer, Inc. shared positive results from phase 2b/3 clinical trial of ritlecitinib for treating alopecia areata. Moreover, the rise in the incidence of cancer cases worldwide is expected to drive the demand for immunotherapy drugs. As per Globocan reports, an estimated 19.3 million new oncology cases were diagnosed in 2020. Moreover, according to the European Society of Medical Oncology, cancer incidence in Europe is anticipated to rise by 21% between 2020 and 2040. Thus, approvals of various immunotherapy drugs for cancer treatment are predicted to increase industry growth.

Immunotherapy Drugs Market Report Highlights:

• The monoclonal antibodies segment accounted for the largest share of 76.2% in 2024. This growth is due to increased research and development in therapeutic monoclonal antibodies and supportive government initiatives.
• The growth can be attributed to the high demand for biologics treatment for various chronic diseases, such as cardiovascular, respiratory, and autoimmune diseases
• The cancer segment dominated the market, accounting for 91.4% of the revenue in 2024 due to the increased incidence of cancer globally and improved healthcare infrastructure in low- and middle-income countries
• The North America immunotherapy market dominated the global market, with a revenue share of 49.9% in 2024
• This is due to the increased adoption of immunotherapy, supportive reimbursement policies, and increased healthcare expenditure in the region

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Immunotherapy Drugs Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. Immunotherapy Drugs Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape.
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Immunotherapy Drugs Market: Drug Type Estimates & Trend Analysis

• 4.1. Drug Type Market Share, 2024 & 2030
• 4.2. Drug Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
• 4.4. Monoclonal Antibodies
  • 4.4.1. Monoclonal Antibodies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Immunomodulator
  • 4.5.1. Immunomodulator Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Vaccine
  • 4.6.1. Vaccine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Immunotherapy Drugs Market: Indication Estimates & Trend Analysis

• 5.1. Indication Market Share, 2024 & 2030
• 5.2. Indication Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
• 5.4. Cancer
  • 5.4.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Autoimmune Diseases
  • 5.5.1. Autoimmune Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Infectious Diseases
  • 5.6.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Immunotherapy Drugs Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 6.4. North America
  • 6.4.1. North America Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Regulatory Framework
    • 6.4.2.3. Competitive Insights
    • 6.4.2.4. U.S. Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Regulatory Framework
    • 6.4.3.3. Competitive Insights
    • 6.4.3.4. Canada Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Regulatory Framework
    • 6.4.4.3. Competitive Insights
    • 6.4.4.4. Mexico Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Regulatory Framework
    • 6.5.2.3. Competitive Insights
    • 6.5.2.4. UK Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Regulatory Framework
    • 6.5.3.3. Competitive Insights
    • 6.5.3.4. Germany Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Regulatory Framework
    • 6.5.4.3. Competitive Insights
    • 6.5.4.4. France Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Regulatory Framework
    • 6.5.5.3. Competitive Insights
    • 6.5.5.4. Italy Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Regulatory Framework
    • 6.5.6.3. Competitive Insights
    • 6.5.6.4. Spain Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Regulatory Framework
    • 6.5.7.3. Competitive Insights
    • 6.5.7.4. Denmark Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Regulatory Framework
    • 6.5.8.3. Competitive Insights
    • 6.5.8.4. Sweden Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Regulatory Framework
    • 6.5.9.3. Competitive Insights
    • 6.5.9.4. Norway Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Regulatory Framework
    • 6.6.2.3. Competitive Insights
    • 6.6.2.4. Japan Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Regulatory Framework
    • 6.6.3.3. Competitive Insights
    • 6.6.3.4. China Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Regulatory Framework
    • 6.6.4.3. Competitive Insights
    • 6.6.4.4. India Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. Thailand
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Regulatory Framework
    • 6.6.5.3. Competitive Insights
    • 6.6.5.4. Thailand Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. South Korea
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Regulatory Framework
    • 6.6.6.3. Competitive Insights
    • 6.6.6.4. South Korea Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Australia
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Regulatory Framework
    • 6.6.7.3. Competitive Insights
    • 6.6.7.4. Australia Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Regulatory Framework
    • 6.7.2.3. Competitive Insights
    • 6.7.2.4. Brazil Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Regulatory Framework
    • 6.7.3.3. Competitive Insights
    • 6.7.3.4. Argentina Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Middle East and Africa
  • 6.8.1. Middle East and Africa Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Regulatory Framework
    • 6.8.2.3. Competitive Insights
    • 6.8.2.4. South Africa Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Regulatory Framework
    • 6.8.3.3. Competitive Insights
    • 6.8.3.4. Saudi Arabia Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Regulatory Framework
    • 6.8.4.3. Competitive Insights
    • 6.8.4.4. UAE Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Regulatory Framework
    • 6.8.5.3. Competitive Insights
    • 6.8.5.4. Kuwait Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. Amgen Inc.
    • 7.5.1.1. Participant's Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Recent Developments/ Strategic Initiatives
  • 7.5.2. Novartis AG
    • 7.5.2.1. Participant's Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Recent Developments/ Strategic Initiatives
  • 7.5.3. AbbVie Inc.
    • 7.5.3.1. Participant's Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Recent Developments/ Strategic Initiatives
  • 7.5.4. Pfizer Inc.
    • 7.5.4.1. Participant's Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Recent Developments/ Strategic Initiatives
  • 7.5.5. F. Hoffmann-La Roche Ltd
    • 7.5.5.1. Participant's Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Recent Developments/ Strategic Initiatives
  • 7.5.6. Johnson & Johnson Services, Inc.
    • 7.5.6.1. Participant's Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Recent Developments/ Strategic Initiatives
  • 7.5.7. AstraZeneca
    • 7.5.7.1. Participant's Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Recent Developments/ Strategic Initiatives
  • 7.5.8. GSK plc.
    • 7.5.8.1. Participant's Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Recent Developments/ Strategic Initiatives
  • 7.5.9. Sanofi
    • 7.5.9.1. Participant's Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Recent Developments/ Strategic Initiatives
  • 7.5.10. Bayer AG
    • 7.5.10.1. Participant's Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Recent Developments/ Strategic Initiatives

관련자료